Terms: = Lung cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Treatment
70 results:
1. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
2. [lung-protective effect of esketamine combined with distal limb ischemic preconditioning in elderly patients undergoing thoracoscopic radical surgery for lung cancer: a randomized controlled trial in 160 cases].
Yang Y; Liu G; Ou Y; Lu W
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Mar; 44(3):484-490. PubMed ID: 38597439
[TBL] [Abstract] [Full Text] [Related]
3. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
4. Plasma spd-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract] [Full Text] [Related]
5. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
[TBL] [Abstract] [Full Text] [Related]
6. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A; Huser J; Schmid S; Schär S; Scherz A; Gautschi O; Mauti L; von Briel T; Waibel C; Wannesson L; Pankovics J; Mark MT; Rothschild SI; Addeo A; Janthur WD; Siano M; Boos L; Britschgi C; Früh M
Lung Cancer; 2024 Jan; 187():107427. PubMed ID: 38043395
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of soluble programmed death-1 ligand-1 of lung cancer patients with different characteristics.
Zhu HB; Song X
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8690-8696. PubMed ID: 37782182
[TBL] [Abstract] [Full Text] [Related]
9. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza A; Mohsen R; Kanbour A; Zar Gul AR; Philip A; Vijayakumar S; Hydrose S; Prabhu KS; Al-Suwaidi AK; Inchakalody VP; Merhi M; Abo El-Ella DM; Tauro MA; Akbar S; Al-Bozom I; Abualainin W; Al-Abdulla R; Sirriya SA; Hassnad S; Uddin S; Mohamed Ibrahim MI; Al Homsi U; Demime S
Front Immunol; 2023; 14():1157100. PubMed ID: 37256148
[TBL] [Abstract] [Full Text] [Related]
10. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H; Nakahara Y; Igarashi Y; Kouro T; Higashijima N; Matsuo N; Murakami S; Wei F; Horaguchi S; Tsuji K; Mano Y; Saito H; Azuma K; Sasada T
Cancer Immunol Immunother; 2023 Aug; 72(8):2829-2840. PubMed ID: 37188764
[TBL] [Abstract] [Full Text] [Related]
11. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (spd-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell lung cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract] [Full Text] [Related]
13. Soluble PD-L1 as a Prognostic Factor for Immunotherapy treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract] [Full Text] [Related]
14. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
[TBL] [Abstract] [Full Text] [Related]
15. Sex difference in the expression of PD-1 of non-small cell lung cancer.
Gu Y; Tang YY; Wan JX; Zou JY; Lu CG; Zhu HS; Sheng SY; Wang YF; Liu HC; Yang J; Hong H
Front Immunol; 2022; 13():1026214. PubMed ID: 36341395
[TBL] [Abstract] [Full Text] [Related]
16. The correlation of serum spd-1 and spd-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.
Ancın B; Özercan MM; Yılmaz YM; Uysal S; Kumbasar U; Sarıbaş Z; Dikmen E; Doğan R; Demircin M
Turk J Med Sci; 2022 Aug; 52(4):1050-1057. PubMed ID: 36326416
[TBL] [Abstract] [Full Text] [Related]
17. Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma.
Zhang L; Jiang B; Lan Z; Yang C; Yao Y; Lin J; Wei Q
Front Immunol; 2022; 13():983570. PubMed ID: 36275753
[TBL] [Abstract] [Full Text] [Related]
18. Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell lung cancer.
Berg J; Halvorsen AR; Bengtson MB; Lindberg M; Halvorsen B; Aukrust P; Helland Å; Ueland T
Front Immunol; 2022; 13():875152. PubMed ID: 35911763
[TBL] [Abstract] [Full Text] [Related]
19. Rescuing cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear spd-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract] [Full Text] [Related]
20. The Change of Soluble Programmed Death Ligand 1 (spd-L1) in Plasma of Small Cell lung cancer and Its Clinical Significance.
Lu F; Dong Y; Li Q; Wang M
Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
[TBL] [Abstract] [Full Text] [Related]
[Next]